Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Alteplase

Mirembe Reed, Connor C. Kerndt  1 , Diala Nicolas  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Alteplase

Mirembe Reed et al.
Free Books & Documents

Excerpt

Alteplase is a thrombolytic agent that is manufactured by recombinant DNA technology. It is FDA approved for use in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters. Off-label indications include catheter-directed thrombolysis in the treatment of peripheral arterial occlusive disease and deep vein thrombosis. This activity outlines the indications, contraindications, activity, adverse events, and toxicity of alteplase in the clinical setting as relates to the essential points necessary for members of an interprofessional team managing the care of patients in need of thrombolytic therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Mirembe Reed declares no relevant financial relationships with ineligible companies.

Disclosure: Connor Kerndt declares no relevant financial relationships with ineligible companies.

Disclosure: Diala Nicolas declares no relevant financial relationships with ineligible companies.

References

    1. Jala S, O'Brien E. Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study. J Neurosci Nurs. 2019 Feb;51(1):21-25. - PubMed
    1. Mosimah CI, Murray PJ, Simpkins JW. Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome. Int J Neurosci. 2019 Jun;129(6):612-618. - PMC - PubMed
    1. Katsanos AH, Tsivgoulis G. Is intravenous thrombolysis still necessary in patients who undergo mechanical thrombectomy? Curr Opin Neurol. 2019 Feb;32(1):3-12. - PubMed
    1. Knecht T, Borlongan C, Dela Peña I. Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator. Brain Circ. 2018 Jul-Sep;4(3):99-108. - PMC - PubMed
    1. da Costa ACC, Ribeiro JM, Vasques CI, De Luca Canto G, Porporatti AL, Dos Reis PED. Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis. Support Care Cancer. 2019 Feb;27(2):407-421. - PubMed

Publication types

LinkOut - more resources